Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer S(+)ibuprofen fever study data needed; FDA committee votes against approval.

This article was originally published in The Tan Sheet

Executive Summary

BAYER S(+)IBUPROFEN FEVER REDUCTION STUDY NEEDED, FDA's Nonprescription Drugs and Arthritis Drugs Advisory Committees concluded at an Oct. 9 joint meeting in Bethesda, Md. The committees voted 9-1 not to recommend Bayer's S(+)ibuprofen (dexibuprofen) 200 mg caplets for approval as an OTC analgesic (NDA 20-373). Bayer's proposed indications are the temporary relief of minor aches and pains associated with the common cold, headache, toothache, muscle aches, back ache, menstrual cramps, minor pain of arthritis and temporary reduction of fever ("The Tan Sheet" Sept. 9, p. 3).

You may also be interested in...



Next Generation OTC Painkillers And Cough Syrup On Cards For German Switch Committee

Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS086207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel